公开(公告)号：US20150210754A1

公开(公告)日：2015-07-30

申请号：US14678319

申请日：2015-04-03

Applicant: Omrix Biopharmaceuticals Ltd.

Inventor： Roni Mintz ,  Oleg Belyaev ,  Israel Nur ,  Liliana Bar ,  Roberto Meidler

IPC: C07K16/06

CPC classification number: C07K16/065 ,  A61K39/39591 ,  A61K2039/505 ,  C07K1/18 ,  C07K2317/10 ,  Y10S530/83 ,  Y10S530/831

Abstract: The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2.

Abstract translation: 本发明涉及减少血栓形成剂的免疫球蛋白组合物及其制备方法。 一种方法包括在高于3.8至等于或低于5.3的pH范围内使含免疫球蛋白的溶液进行负阳离子交换层析。 该溶液也可以在7至8.2范围内的pH下进行阴离子交换层析。

公开(公告)号：US06716434B1

公开(公告)日：2004-04-06

申请号：US09666009

申请日：2000-09-19

Applicant: Daniel R. Ansley ,  Kenneth O. Willeford

Inventor： Daniel R. Ansley ,  Kenneth O. Willeford

IPC: A61K3939

CPC classification number: A61K39/39 ,  A61K35/14 ,  Y10S514/885 ,  Y10S530/83

Abstract: This invention relates to compositions utilized to modulate the immune system of non-mammalian vertebrates. More particularly, the present invention relates to the use of low molecular weight substantially immunoglobulin free fractions isolated from mammals to induce a stimulated immune response in non-mammalian vertebrates.

Abstract translation: 本发明涉及用于调节非哺乳动物脊椎动物免疫系统的组合物。 更具体地，本发明涉及从哺乳动物分离的低分子量基本上免疫球蛋白的级分在非哺乳动物脊椎动物中诱导刺激的免疫应答的用途。

公开(公告)号：US06525176B1

公开(公告)日：2003-02-25

申请号：US09612592

申请日：2000-07-07

Applicant: Vivian W. Lee ,  Kris P. Antonsen

Inventor： Vivian W. Lee ,  Kris P. Antonsen

IPC: C07K100

CPC classification number: C07K14/8125 ,  Y10S530/83

Abstract: A method for purifying human or other alpha-l proteinase inhibitor (&agr;1-PI) from a solution (which may be derived from the milk of a transgenic animal expressing the &agr;1-PI) which comprises contacting the solution with a cation exchange substrate under conditions sufficient to bind non-tg-&agr;1-PI contaminants to the substrate while not substantially binding tg &agr;1-PI to the substrate. Using the preferred embodiment, the purified tg &agr;1-PI contains as little as 40 pg non-&agr;1-PI-whey protein per mg total protein.

Abstract translation: 从溶液（其可以衍生自表达α1-PI的转基因动物的乳中）纯化人或其他α-1蛋白酶抑制剂（α1-P​​I）的方法，其包括在条件下使所述溶液与阳离子交换底物接触 足以将非tg-α1-PI污染物结合到基底上，而基本上不结合tgα1-PI。 使用优选的实施方案，纯化的tgα1-PI每mg总蛋白含有少至40pg非α1-PI-乳清蛋白。

公开(公告)号：US20020048608A1

公开(公告)日：2002-04-25

申请号：US09808840

申请日：2001-03-15

Inventor： Tsuneo Hattori ,  Yukinori Takahashi ,  Yoshihiro Tachikawa

IPC: A61K035/64 ,  A61K038/38 ,  A61K031/722

CPC classification number: A61K35/16 ,  A61K31/722 ,  Y10S530/83

Abstract: The goal of the present invention is to provide substances to prevent diseases by activating inherently possessed functions, for cultured fishes and shellfishes and livestock with tendency of decreased immune function due to densely populated breeding environment, and for humans with tendency of easily lowered immune functions due to complicated social structures and aging. The present invention expresses marked effect in preventing infection and cancer by administrating appropriate dose of swine plasma, swine plasma albumin, peptides isolated from swine plasma and swine plasma albumin, and swine plasma mixture, among others including fine powder of Crustacea (including crust of Crustacea), to activate immune function of Crustacea, Pisces, Aves, Mammals, and humans.

Abstract translation: 本发明的目的是提供通过激活固有的功能来预防疾病的物质，对于培养的鱼类和贝类以及具有由于人口稠密的繁殖环境而引起的免疫功能降低的趋势的人以及具有易于降低免疫功能的趋势的人 复杂的社会结构和衰老。 本发明通过施用适当剂量的猪血浆，猪血浆白蛋白，从猪血浆和猪血浆白蛋白中分离的肽，以及猪血浆混合物等包括细粉甲壳纲（包括甲壳类的地壳），表达了预防感染和癌症的显着效果 ），以激活甲壳纲，双鱼座，艾夫斯，哺乳动物和人类的免疫功能。

公开(公告)号：US06191112B1

公开(公告)日：2001-02-20

申请号：US09388758

申请日：1999-09-02

Applicant: Nadav Friedmann ,  Patrick J. Scannon ,  Sander J. H. van Deventer ,  Marijke A. M. von der Mohlen ,  Nancy Wedel

Inventor： Nadav Friedmann ,  Patrick J. Scannon ,  Sander J. H. van Deventer ,  Marijke A. M. von der Mohlen ,  Nancy Wedel

IPC: A61K3800

CPC classification number: C07K14/4742 ,  A61K38/1751 ,  Y10S514/921 ,  Y10S530/82 ,  Y10S530/83 ,  A61K2300/00

Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).

Abstract translation: 公开了通过施用杀菌/渗透性增加（BPI）蛋白质产物来治疗暴露于细菌内毒素的人的方法。 在这种治疗后，观察到血清学和血液学上可证实的缓解内毒素介导的循环细胞因子，纤维蛋白溶解和凝血因子的增加以及淋巴细胞计数的变化。 还观察到减轻内毒素介导的全身血管阻力指数（SVRI）的降低以及心脏指数（CI）的伴随增加。

公开(公告)号：US6093804A

公开(公告)日：2000-07-25

申请号：US159461

申请日：1998-09-24

Applicant: Annemarie H. Ralston ,  William H. Drohan

Inventor： Annemarie H. Ralston ,  William H. Drohan

IPC: A61K38/00 ,  C07K14/81 ,  C07K14/00 ,  A23J1/00 ,  A61K35/14

CPC classification number: C07K14/8125 ,  A61K38/00 ,  Y10S530/83

Abstract: The methods of the present invention provide a simple means for separating active and inactive Alpha Proteinase Inhibitor (API). The methods further provide means for purifying API at high yield (>70%), and at levels of purity (>90%) and activity (>90%) not heretofore available. Moreover, the methods of the present invention are simple (i.e., two chromatographic steps) and efficient; and are thus especially suitable to large scale purification processes. These methods will contribute substantially to alleviating the unmet demand for API for therapeutic purposes.

Abstract translation: 本发明的方法提供了用于分离活性和非活性的Alpha蛋白酶抑制剂（API）的简单方法。 该方法进一步提供了以高产率（> 70％）和纯度（> 90％）和活性（> 90％）纯化API的方式。 此外，本发明的方法简单（即两个色谱步骤）并且效率高; 因此特别适用于大规模的纯化工艺。 这些方法将大大有助于减轻API对治疗目的的未满足需求。

公开(公告)号：US6037457A

公开(公告)日：2000-03-14

申请号：US792108

申请日：1997-01-31

Applicant: Susan T. Lord

Inventor： Susan T. Lord

IPC: C07K14/75 ,  C07K1/22 ,  C07K1/18 ,  C12P21/02

CPC classification number: C07K14/75 ,  Y10S530/83

Abstract: The present invention provides methods of producing recombinant fibrinogen in a long-term mammalian cell culture system. Disclosed is a method for the production of recombinant fibrinogen, comprising: growing mammalian cells that express recombinant fibrinogen in a serum-free medium for a time of at least one month at a level of at least 5 .mu.g/ml; and then collecting portions of the conditioned medium at least twice during the culturing time of at least one month, with each portion containing at least 5 .mu.g/ml of recombinant fibrinogen. Also disclosed is a method for the production of recombinant fibrinogen, comprising: growing mammalian cells that express recombinant fibrinogen in a serum-free medium at a level greater than 1 .mu.g/ml; collecting at least a portion of the conditioned medium, and then purifying the fibrinogen from the medium by anion-exchange chromatography or affinity chromatography. In some embodiments of the invention, the medium is concentrated prior to the step of purifying the fibrinogen. In alternate embodiments, both the concentrating and purifying steps are carried out in the presence of at least one protease inhibitor.

Abstract translation: 本发明提供了在长期哺乳动物细胞培养系统中生产重组纤维蛋白原的方法。 公开了一种生产重组纤维蛋白原的方法，包括：生长哺乳动物细胞，其在无血清培养基中表达重组纤维蛋白原至少一个月至少5μg/ ml的水平; 然后在至少一个月的培养时间内收集部分条件培养基至少两次，每个部分含有至少5μg/ ml的重组纤维蛋白原。 还公开了一种生产重组纤维蛋白原的方法，包括：生长在无血清培养基中以大于1μg/ ml的水平表达重组纤维蛋白原的哺乳动物细胞; 收集条件培养基的至少一部分，然后通过阴离子交换层析或亲和层析从培养基中纯化纤维蛋白原。 在本发明的一些实施方案中，在纯化纤维蛋白原的步骤之前将培养基浓缩。 在替代实施方案中，浓缩和纯化步骤都在至少一种蛋白酶抑制剂的存在下进行。

公开(公告)号：US5990086A

公开(公告)日：1999-11-23

申请号：US203159

申请日：1998-12-01

Applicant: Brett P. Giroir ,  Patrick J. Scannon

Inventor： Brett P. Giroir ,  Patrick J. Scannon

IPC: C12N15/09 ,  A61K31/00 ,  A61K38/00 ,  A61K38/17 ,  A61P31/00 ,  C07K14/47 ,  C12P21/02 ,  A61K35/14

CPC classification number: C07K14/4742 ,  A61K38/1751 ,  Y10S514/898 ,  Y10S514/921 ,  Y10S530/829 ,  Y10S530/83

Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.

公开(公告)号：US5990079A

公开(公告)日：1999-11-23

申请号：US16400

申请日：1998-01-30

Applicant: David L. Wolf ,  Uma Sinha

Inventor： David L. Wolf ,  Uma Sinha

IPC: C12N15/09 ,  A61K38/00 ,  A61K38/43 ,  A61K38/46 ,  A61K38/48 ,  A61P7/04 ,  C07K14/745 ,  C12N9/64 ,  C12P21/00 ,  A61K38/36 ,  A61F13/00 ,  A61K35/16 ,  C07K14/435

CPC classification number: C12N9/6464 ,  C07K14/745 ,  C12N9/6432 ,  C12N9/647 ,  C12Y304/21006 ,  C12Y304/21069 ,  A61K38/00 ,  Y10S514/834 ,  Y10S530/83

Abstract: Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilia conditions. These modified forms of the blood factor may be acylated forms which are slowly deacylated in vivo.

Abstract translation: 短暂失活的血液因子的类似物可用于治疗以血栓形成为特征的疾病。 此外，在血清中产生活性血因子但具有延长半衰期的活化血液因子的修饰形式可用于治疗血友病病症。 血液因子的这些修饰形式可以是在体内缓慢脱酰基化的酰化形式。

公开(公告)号：US5733885A

公开(公告)日：1998-03-31

申请号：US678594

申请日：1996-07-15

Applicant: Johann Eibl ,  Gabriela Hummel ,  Gerda Redl ,  Thomas Seelich ,  Peter Turecek ,  Gunter Wober

Inventor： Johann Eibl ,  Gabriela Hummel ,  Gerda Redl ,  Thomas Seelich ,  Peter Turecek ,  Gunter Wober

IPC: A61K38/16 ,  A61K35/14 ,  A61K38/00 ,  A61K38/43 ,  A61K38/46 ,  A61K38/48 ,  A61K47/00 ,  A61L2/00 ,  C12N5/00 ,  C07K14/475 ,  C12N7/06 ,  A61L2/16

CPC classification number: A61K35/14 ,  A61L2/0023 ,  A61L2/0088 ,  Y10S530/83

Abstract: In a method of producing a virus-safe biological preparation by heating while preserving a least 50% of its biologic activity, a biologially compatible tenside is added to the preparation before heating and heating is carried out in the presence of the same, whereupon the tenside, preferably, is eliminated.

Abstract translation: 在通过加热同时保存其生物活性的至少50％来生产病毒安全的生物制剂的方法中，在加热和加热之前，将生物相容的表面活性剂加入到制剂中，然后在其上进行表面活性剂 ，优选地被消除。